Lupin Q1 Preview: Steady US sales, market share gains to boost profits

Q: How long will it take to read this news story?

The story "Lupin Q1 Preview: Steady US sales, market share gains to boost profits" has 478 words across 21 sentences, which will take approximately 2 - 4 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Lupin Q1 Preview: Steady US sales, market share gains to boost profits" was covered 9 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 275 news stories per day. It's most recent story was published 3 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #21929782</li><li>URL: https://beamstart.com/news/lupin-q1-preview-steady-us-17228514791140</li></ul>

Business Standard Logo Business Standard 9h ago

Lupin Q1 Preview: Steady US sales, market share gains to boost profits - Business Standard

Quick Summary:

According to the brokerage, the key downside risks include lower-than-expected domestic growth and delays in Spiriva market share expansion.

Domestic sales are predicted to grow 10 per cent year-on-year, with overall sales increasing 8 per cent Y-o-Y.

Brokerage estimates suggest that the pharma major is expected to see strong double-digit growth in the bottom line and single-digit growth in the top line year-on-year (Y-o-Y).